Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06393712 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy
A Phase 2 study of Cerebral Amyloid Angiopathy, sponsored by Alnylam Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
- 20
- Study locations
NCT06393712 is a Phase 2 study of Cerebral Amyloid Angiopathy that is actively recruiting participants, run by Alnylam Pharmaceuticals. The registered enrollment target is 200 participants. The trial reports 20 study locations across 12 states.
The verdict
NCT06393712, a Phase 2 study of Cerebral Amyloid Angiopathy, is actively recruiting participants, sponsored by Alnylam Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to evaluate the effect of ALN-APP on measures of CAA disease progression and to characterize the safety, tolerability, and pharmacodynamics (PD) of ALN-APP in adult patients with sporadic CAA (sCAA) and Dutch-type CAA (D-CAA). The study will be conducted over 2 periods: a 24-month double-blind treatment period and an optional 18-month open-label extension (OLE) period. The estimated duration of study participation, inclusive of screening, treatment, and additional safety follow-up, is up to 50 months.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG ALN-APP
Study Locations (20)
California
- Clinical Trial Site - Los Angeles
- Clinical Trial Site - Orange
- Clinical Trial Site - Palo Alto
- Clinical Trial Site - Sacramento
- Clinical Trial Site - San Francisco
Florida
- Clinical Trial Site - Gainesville
- Clinical Trial Site - Jacksonville
- Clinical Trial Site - Maitland
- Clinical Trial Site - Naples
Massachusetts
- Clinical Trial Site - Boston
- Clinical Trial Site - Plymouth
Colorado
- Clinical Trial Site - Aurora
Connecticut
- Clinical Trial Site - New Haven
Illinois
- Clinical Trial Site - Chicago
Kentucky
- Clinical Trial Site - Lexington
Louisiana
- Clinical Trial Site - New Orleans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2024-05-17 |
| Est. Completion | 2029-12-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06393712
The ClinicalTrials.gov registry entry for NCT06393712 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alnylam Pharmaceuticals, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cerebral Amyloid Angiopathy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06393712 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Florida, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06393712 about?
NCT06393712 is a clinical study titled "A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy". The purpose of the study is to evaluate the effect of ALN-APP on measures of CAA disease progression and to characterize the safety, tolerability, and pharmacodynamics (PD) of ALN-APP in adult patients with sporadic CAA (sCAA) and Dutch-type CAA (D-CAA). The study will be conducted over 2 periods: a...
What is the current status of trial NCT06393712?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2024-05-17. Estimated completion is 2029-12-14.
What conditions does trial NCT06393712 study?
This clinical trial studies the following conditions: Cerebral Amyloid Angiopathy.
What interventions are being tested in trial NCT06393712?
The interventions under investigation include: Placebo (DRUG), ALN-APP (DRUG).
Who is sponsoring clinical trial NCT06393712?
This trial is sponsored by Alnylam Pharmaceuticals, which has 49 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06393712 being conducted?
This trial has 20 study locations across California, Colorado, Connecticut, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cerebral Amyloid Angiopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.